Dermatol. praxi. 2020;14(2):91-95 | DOI: 10.36290/der.2020.016

Risankizumab (Skyrizi)

MUDr. Jiří Horažďovský, Ph.D.
Dermatovenerologické oddělení Nemocnice České Budějovice, a. s.

Imunopatogenetic mechanisms of psoriasis extend our possibilities for new targeting therapy. The crucial importance of interleukin 23 (IL-23) was recognized. Risankizumab is the next biologic drug with target inhibition of IL-23. Article summarizes the therapeuric potential of this drug and gives the first clinical experiences by myself.

Keywords: psoriasis, interleukin 23, biologic therapy, risankizumab.

Published: June 18, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horažďovský J. Risankizumab (Skyrizi). Dermatol. praxi. 2020;14(2):91-95. doi: 10.36290/der.2020.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun 2015; 64: 66-73. Go to original source... Go to PubMed...
    2. WHO. 2016 Global report on psoriasis. 2016. Dostupné z: http://www.who.int/ iris/handle/10665/204417 (accessed Sept 12, 2018).
    3. Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017; 76: 377-390. Go to original source... Go to PubMed...
    4. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population‑based study. JAMA Dermatol 2013; 149: 1173-1179. Go to original source...
    5. Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23/T<sub>H</sub> 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 1616-1626. Go to original source...
    6. Cetkovská P, Kojanová M, Arenberger P, Fabiánová J. Současný stav moderní léčby psoriázy - aktualizovaná doporučení ČDS JEP k cílené léčbě závažné chronické psoriázy. Farmakoterapie 2020; 16(supplementum 2): 5-28.
    7. Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018; 201(6). Go to original source...
    8. Di Meglio P, Nestle FO. The role of IL-23 in the immunopathogenesis of psoriasis. F1000 Biol Rep. 2010; 2: 40. Go to original source... Go to PubMed...
    9. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014; 14(9): 585-600. Go to original source... Go to PubMed...
    10. Cheuk S, et al. Epidermal Th22 and Tc17 Cells From a Localized Disease Memmory in ClinicallyHealed Psoriasis. J Immunol 2014; 192: 3111-3120. Go to original source...
    11. McKeage K, Duggan S. Risankizumab: First global approval. Drugs 2019; 79: 893-900. Go to original source... Go to PubMed...
    12. Skyrizi, Souhrn informací o přípravku, 2019.
    13. Torres T. Selective interleukin-23 p19 inhibition: Another game changer in psoriasis? Focus on risankizumab. Drugs 2017; 77: 1493-1503. Go to original source... Go to PubMed...
    14. Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus ustekinumab for moderate‑to‑severe plaque psoriasis. N Engl J Med 2017; 376: 1551-1560. Go to original source...
    15. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate‑to‑severe plaque psoriasis (UltlMMa-1 and UltlMMa-2): results from two double‑blind, randomised, placebo‑controlled and ustekinumab‑controlled phase 3 trials. Lancet 2018; 392: 650-661. Go to original source...
    16. Blauvelt A, Papp KA, Gooderham M, et al. Risankizumab efficacy/safety in moderate‑to‑severe plaque psoriasis: 16-week results from immhance. Acta Derm Venereol 2018; 98(Suppl 219): 30(abstract P066).
    17. Langley R, Blauvelt A, Gooderham M, et al. Efficacy and safety of continuous Q12W risankizumab versus treatment withdrawal: results from the phase 3 IMMhance trial. 2019 AAD Annual Meeting, poster 10093.
    18. Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with adalimumab in patients with moderate‑to‑severe plaque psoriasis (IMMvent): a randomised, double- blind, active‑comparator‑controlled phase 3 trial. Lancet 2019; 394(10198): 576-586. Go to original source...
    19. Leonardi C, Bachelez H, Wu JJ, et al. Long‑term safety of risankizumab in patients with moderate to severe psoriasis: analysis of pooled clinical trial data. 2019 AAD Annual Meeting, poster 9891.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.